CJC-1295 vs Tesamorelin

Name: CJC-1295 vs Tesamorelin
Published: 2026-10-23

Updated Oct 23, 202610 sources

Key differences

1Tesamorelin is full-length GHRH(1-44) with a stabilizing cap. It is FDA approved and has Phase 3 visceral-fat data. CJC-1295 was never approved.
2CJC-1295 with DAC lasts days; tesamorelin's half-life is minutes.
3CJC-1295 with DAC lasts days; tesamorelin's half-life is minutes. CJC-1295 was never approved.

Facts from each record, in the same words as their own pages.

CJC-1295 and Tesamorelin side by side
	CJC-1295	Tesamorelin
Category	GH axis	GH axis
Evidence	Limited human data	Strong human trials
FDA status	Not FDA approvedRegulatory	FDA approved as Egrifta +2Regulatory
WADA	Prohibited	Prohibited
Half-life	With DAC: 5.8 to 8.1 days in healthy adults. Without DAC: about 30 minutes per guides, never measured in humans.Competitor guide	8 minutes (Egrifta SV) and 11 minutes (Egrifta WR) in healthy subjects. Older figures for the original formulation are 26 to 38 minutes.Clinical study
Routes	Subcutaneous injection	Subcutaneous injection
Reported doses	0.4 to 2 mg (subcutaneous injection) 100 to 400 mcg (subcutaneous injection)	1 to 2 mg (subcutaneous injection) 125 to 1,000 mcg (subcutaneous injection)
Most cited frequency	1 to 2 mg a week, split into 1 or 2 injections	Once daily
Vial sizes	2 mg, 5 mgCompetitor guide	2 mg, 5 mg, 10 mg, 20 mgCompetitor guide
Mixed vial keeps	Fridge, 2 to 8 °C, and avoid freeze-thaw.Competitor guide	Egrifta SV: use right after mixing and discard the rest.Competitor guide
Protocols on file	9	11

Doses shown are what sources report, labelled by origin. Not medical advice.

10 sources, each checked by date. Record updated Oct 23, 2026. Numbers are restated in our own words and labelled by where they came from.